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Abstract — Aims: To establish a nutritional and constitutional profile concerning the micronutrient plasma concentration of patients
who suffer from AWS. Method: Observational case control study to determine whether patients who exhibited symptoms of AWS
(N = 60) had micronutrient plasmatic concentration deficiencies when compared with healthy controls (N = 34). Results: There were
statistically significant differences between the concentrations of nutrients that are correlated with glutamate hyperactivity (zinc, magne-
sium and folate/vitamin B12/homocysteine). Conclusion: Evidence from literature and our experiment suggests that brain activity, espe-
cially the glutamatergic system, might be directly involved in micronutrient concentrations. Therefore, their supplementation to the
AWS patient might improve symptom evolution.
INTRODUCTION
Alcohol withdrawal syndrome (AWS) is a complex psychiatric
entity defined by the sudden stop in alcohol intake by a vulner-
able patient who has already developed alcohol dependence
(Mitchell and Herlong, 1986; Lieber, 2003;Moreno Otero and
Cortés, 2008). It is composed of several physical manifesta-
tions (nausea, vomiting, heavy sweating hypertension) and
psychiatric symptoms (hallucinations, psychomotor agitation
and other possible psychotic-like behaviour) (Douaihy et al.,
2013). Current treatments seek to control symptoms by using
substances that mimic ethanol behaviour in GABAergic recep-
tor systems, which reduces immediate symptoms but does not
address the full aetiology of AWS (Noori et al., 2012).
It is established that alcohol-dependent patients tend to
several nutritional deficiency syndromes, such as Wernicke–
Korsakoff syndrome (thiamine deficiency), pellagra (B3 defi-
ciency), protein caloric deficiency and syndromes due to
malabsorption in the upper and lower intestines (Lieber, 2003;
Delgado-Sanchez et al., 2008; Moreno Otero and Cortés,
2008). This tendency is related to the combination of the dam-
aging effect of ethanol on mucous membranes in the digestive
tract, which leads to chronic bleeding, inflammation, and
eventual loss of functions in the stomach and upper and lower
intestines (Lieber, 2003;Moreno Otero and Cortés, 2008), and
malnourishment of the alcohol-dependent patient who may,
for a number of reasons, have a poor diet. These reasons may
include: (a) economic entanglement with alcohol dependence,
in which domestic budget is used to acquire and consume
alcohol instead of essential items; (b) the anorectic effect of
alcohol in hunger and satiety centres of the hypothalamus; and
(c) the loss of social and work activity roles due to depend-
ence, causing loss of acquisitive power, which limits diet
variety (Mitchell and Herlong, 1986; Lieber, 2003; Moreno
Otero and Cortés, 2008;Noori et al., 2012).
Certain nutrients have been shown to affect the central
nervous system pathways. These nutrients are ingested and
needed in smaller amounts than protein or carbohydrates.
Some nutrients, such as magnesium and zinc (Li-Smerin
et al., 2001; Evans et al., 2007; Milton et al., 2008; Nechifor,
2008; Witkiewitz 2008; Prior and Galduróz, 2011), affect the
glutamate pathway by controlling neuron excitotoxicity and
death. Other nutrients function as components of the neuronal
membrane (vitamin D), enabling full transport function,
release of toxins to the extracellular environment; controlling
second messenger concentration; and preventing apoptosis,
malfunction of electrical and chemical transmission of signals
in neuron pathways and the expression of receptors in the
membrane (Ueland and Refsum, 1989; Lim and Heo, 2002;
Guo et al., 2006; Harms et al., 2011; Sutachan et al., 2012).
Many studies have demonstrated that element deficiency (such
as folate, vitamin A and vitamin D, deficiencies) may be
important in drug dependence, and may have an effect in de-
stabilizing glutamatergic, serotoninergic and dopaminergic path-
ways, which contribute to the degenerating mental state these
patients experience (Sullivan et al., 1989; Allen 2008; Cylwik
et al., 2010; Sutachan et al., 2012). Other nutrients though im-
portant to normal brain function, have not been correlated
with acute neuron malfunction in illnesses such as AWS.
Few studies have tried to establish a nutritional profile of
alcohol-dependent patients, even those who are admitted in
support services. Quantifying their proteic and lipid losses, as
well as their micronutrient concentration, compared with their
previous states, may be crucial for understanding the physical
and metabolic causes and effects in AWS, and for establishing
a possible treatment for their symptoms and conditions.
Therefore, the objective of this study was to establish a nutri-
tional and constitutional profile concerning the micronutrient
plasma concentration of patients who suffer from AWS.
METHODS
This study was an observational, case control study involving
sixty patients enrolled in the Centro de Referência de
Tratamento de Álcool, Tabaco e outras Drogas (CRATOD),
a multiprofessional institution dedicated to the treatment of
drug-dependent patients with a focus on alcohol depend-
ence. Inclusion criteria were male gender, age between 20
and 60 years, and no other psychiatric comorbidity diagno-
ses other than alcohol dependence. Exclusion criteria were
any psychiatric comorbidity diagnoses other than AWS; use
of any psychoactive drugs other than symptomatic benzodia-
zepines for withdrawal symptoms; diagnosis of hepatic cir-
rhosis or of any metabolic diseases. Tobacco users were not
excluded.
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The severity of withdrawal symptoms was quantified using
the Clinical Institute Withdrawal Assessment for Alcohol
(CIWAA), which comprises 10 questions concerning the
occurrence of common AWS symptoms and measures their
intensity, ranging from 1 (weak) to 7 (very severe). The
maximum score is 67, and any score >10 indicates that
pharmacological treatment of symptoms is appropriate (Sullivan
et al., 1989). The scale was applied at the moment of enrolment
and 2 weeks after enrolment.
The following micronutrients were selected for laboratory
testing: magnesium, zinc, folate, cianocobalamine (vitamin
B12), retinoic acid (vitamin A), 1,25 Di-hydroxi vitamin D3,
homocysteine and serum iron. Two blood samples were col-
lected from each patient, at the moment of enrolment, when
the patients exhibited several physical and mental manifesta-
tions of AWS, and 2 weeks after enrolment, when many
patients exhibited clinical improvement. Laboratory data from
patients were compared with data from healthy control in-
dividuals (N = 34) who were members of the Department of
Psychobiology of Universidade Federal de São Paulo
(UNIFESP) and had no history of mental disorder, substance
abuse, physical comorbidities or withdrawal symptoms at the
time of the single blood sample collection.
The project was approved by the Committee of Ethics in
Research of the Universidade Federal de São Paulo (# 1451/
11). Each participant provided informed consent and was
assured the right to quit the study at any time, as well as confi-
dentiality of identity.
Statistical analysis
The comparison of the case group at enrolment (t = 0) and
after 2 weeks of enrolment (t = 2w) in their CIWAA scores
and micronutrient serum concentration was analysed using
paired Student’s t-test. The unpaired t Student test was used to
detect changes in micronutrient serum concentration between
the case and control groups. Pearson’s r correlation test was
performed between CIWAA (t0, t2w) and micronutrient
values at baseline. Bias-corrected and accelerated (BCa) boot-
strap (1000 replications) was used to estimate 95% confidence
intervals (CI) for the correlation coefficient (Fethney, 2010).
Correlations were considered significant for P < 0.05 and a CI
not including zero (19). For all analyses the predetermined
significance level was P < 0.05.
RESULTS
The age mean ± standard deviation for the alcohol-dependent
group was 39.7 ± 4.54 years, all males, with a mean education
level of 8.2 ± 1.2 years. The control group had a mean age of
31.0 ± 2.1 years, with a mean education level of 16 ± 0.6
years. This shows a statistically significant difference between
groups (P < 0.001 for both age and educational level), which
may indicate a greater predisposition to alcohol dependence
amongst the less educated.
The mean Clinical Institute Withdrawal Assessment for
Alcohol (CIWAA) scores at t = 0 was 25.5 ± 10.8, which
reduced to 12.7 ± 2.1 in 2 weeks P < 0.0001 (paired Student’s
t-test).
Table 1 compares the groups on micronutrient concentration
at t = 0 and t = 2w. Only transferrin and vitamin A did not
differ between control group and case group at t = 0. Between
t = 0 and t = 2w, there was a significant decrease in transferrin
and homocysteine concentrations, and an increase in magne-
sium, vitamin B12 and zinc (P < 0.001). The changes coin-
cided with improvement in AWS symptoms in the case group
(Table 2).
As shown in Table 1, there was a significant negative correl-
ation between CIWAA and Mg at baseline (BCa 95%
CI = −0.19, −0.55; P < 0.01).CIWAA at t2 also correlated
negatively with baseline Mg (BCa 95% CI = −0.07, −0.56;
P < 0.01) and positively with baseline Vitamin D (BCa 95%
CI = 0.07, 0.60; P < 0.01). The following were obtained from
the relevant Pearson’s correlations—CIWAA at t = 0 paired
with magnesium concentrations (R2 = 0.16), CIWAA at t = 2w
paired with magnesium concentrations (R2 = 0.12), CIWAA at
t = 2w paired with vitamin D3 concentrations (R2 = 0.16)
(Figs 1 and 2).
Amongst the control group, the medium concentration of
vitamin D3 was 16.9 ± 6.1, which is low compared to the
standard medium of 30 in the general population. No such
deficiency was documented in the case group at either time-
point. This result is most likely due to differences in sun
exposure due to personal and occupational activities. It is
notable that the control group members were workers and stu-
dents from the Department of Psychobiology, with work shifts
of mostly indoor activity ranging from 8 to 12 h in daytime.
The case group was composed of street and construction
workers, and venders, with much more exposure to sunlight.
DISCUSSION
Our study demonstrated a possible connection between micro-
nutrient deficiency and severity of AWS. Although we could
not categorically state whether a single nutrient or any combi-
nations of nutrients are singlehandedly correlated with symp-
toms, this study offers a treatment hypothesis for AWS. Two
nutrients studied here may be highlighted as having a more
direct role in the establishment of AWS: magnesium and
vitamin D.
Table 1. Micronutrient concentration (median ± SD), comparison between
alcohol dependents (N = 60) and healthy controls (N = 34)
Micronutrients
Groups
Control Alcohol Dependents
Time zero
(pre-treatment)
Time 2 weeks
(post-treatment)
Ferritin 62.4 ± 40.9 18.6 ± 4.6* 20.0 ± 9.4†
Folate 14.9 ± 4.7 2.4 ± 0.2* 2.4 ± 0.2†
Homocysteine 9.1 ± 2.2 21.3 ± 4.6* 9.8 ± 1.8#
Magnesium 2.29 ± 0.1 0.7 ± 0.1* 1.3 ± 0.4†,#
Transferrin 290.7 ± 38.4 284.4 ± 90.5 240.7 ± 35.7†,#
Vita A 24.2 ± 1.0 24.3 ± 5.6 25.7 ± 5.9
Vita B12 272.96 ± 107.8 93.9 ± 8.6* 128.3 ± 15.2†,#
Vita D 16.9 ± 6.1 33.7 ± 3.2* 34.1 ± 3.5†
Zinc 94.9 ± 19.6 38.1 ± 5.2* 75.8 ± 13.0†,#
*P < 0.01 (paired ‘t’ Student test)—Comparison between control group and
alcohol-dependent group at Time zero.
†P < 0.01 (paired ‘t’ Student test)—Comparison between control group and
alcohol-dependent group at Time 2 weeks.
#P < 0.01 (paired ‘t’ Student test)—Comparison between alcohol-dependent
group at times zero and 2 weeks.
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These nutrients participate in the N-methyl-D-aspartate
receptor (NMDA)-mediated excitotoxicity observed in many
psychiatric conditions, including, but not limited to, AWS
(Sullivan et al., 1989; Halliwell, 1992; Robinson and Berridge,
1993; Littleton, 1998; Bisaga et al., 2000; Sobolevsky and
Yelshansky, 2000). The glutamatergic excitatory pathways are
hyperactive in withdrawal patients, producing greater calcium
influx through NMDA channels; an increase in nitric oxide
synthetase activity and concentration; an increase in reactive
oxygen species, and greater neuron membrane damage, loss of
function and death (Halliwell, 1992; Robinson and Berridge,
1993; Littleton, 1998; Bisaga et al., 2000; Schneider et al.,
2000; Sobolevsky and Yelshansky, 2000; Li-Smerin et al., 2001;
Evans et al., 2007).
Magnesium is a natural NMDA receptor antagonist
(Li-Smerin et al., 2001), reducing neuron excitotoxicity
induced by glutamate hyperactivity. It has been hypothesized
that the decrease in concentrations in magnesium, zinc and
their coenzymes (mainly thiamine) is associated with sudden
lack of ethanol intake, responsible for the severity of AWS
symptoms. The increase in plasma concentrations of these
micronutrients, after the period of 2 weeks, might be asso-
ciated with mitigating symptoms, mainly due to decreased
NMDA receptor activity (Robinson and Berridge, 1993;
Frederickson et al., 2000; Cohen-Kfir et al., 2005).
Other nutrients, such as vitamin D, seem to indirectly inter-
fere with neuron membrane integrity and function, and their
shortage may contribute to neuron malfunction and death in
Fig. 1. Correlation plots between CIWAAvalues × magnesium serum concentration in the case group (N = 60) and enrolment (1) and after 2 weeks (2).
Table 2. Pearson’s correlations between CIWAA scores and micronutrients concentrations in the case group (N = 60) and enrolment (1) and after 2 weeks (2)
CIWAA_1 CIWAA_2 Mg_1 Zinc_1 Folate_1 Vita B12_1 Vita A_1 Vita D_1 HYC_1 Ferritin_1 Transferrin_1
CIWAA_1
CIWAA_2 0.11
Mg_1 −0.39* −0.34*
Zinc_1 −0.08 0.19 −0.19
Folate_1 −0.18 0.12 0.04 0.26
Vita B12_1 0.04 −0.11 −0.10 −0.01 0.06
Vita A_1 −0.05 0.08 −0.06 −0.00 0.01 0.15
Vita D_1 0.00 0.39* −0.11 −0.08 0.09 −0.41 −0.40
HYC_1 0.10 −0.02 −0.15 0.26 −0.03 −0.05 −0.04 −0.05
Ferritin_1 −0.08 0.05 0.19 −0.02 0.12 −0.43 −0.03 0.33 −0.08
Transferrin_1 −0.07 −0.06 0.01 0.22 0.30 −0.05 0.06 −0.01 0.03 −0.03
Mg, magnesium; HYC, homocysteine.
*P < 0.01.
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the same way glutamate hyperactivity does (Schneider et al.,
2000; Kim et al., 2009; González-Reimers et al., 2011;
Neupane et al., 2013).
Nutrient supplementation during AWS, according to our
hypothesis, would most likely mitigate glutamatergic activa-
tion, preserving neuron integrity. New and broader studies are
needed to establish whether the supplementation of selected
nutrients via oral or parenteral methods reduces AWS symp-
toms and the physical and mental stress in these patients, thus
corroborating the nutritional hypothesis of AWS.
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